Mitogen-Activated Protein Kinase Signaling Enhances Sodium Iodide Symporter Function and Efficacy of Radioiodide Therapy in Nonthyroidal Cancer Cells
Open Access
- 7 November 2008
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 49 (12), 1966-1972
- https://doi.org/10.2967/jnumed.108.055764
Abstract
Although the success of sodium/iodide symporter (NIS) gene–based cancer therapy is critically dependent on the level of radioiodide accumulation attained, recent evidence indicates that successful therapy relies not solely on NIS amount but also crucially on its functional activity. In this study, we investigated the role of kinase-linked signaling on the regulation of NIS function in cancer cells. Methods: T47D human breast cancer and PC-12 rat pheochromocytoma cells were transduced with the human NIS genes via an adenoviral vector. Cells were measured for 125I uptake, and the effects of activation or inhibition of protein kinase C (PKC) and mitogen-activated protein (MAP) kinase pathways were evaluated. Membrane localization of NIS was evaluated by biotinylation-immunoblotting and confocal microscopy. 131I-mediated cancer cell killing was evaluated by clonogenic assays. Results: NIS function was acutely reduced by short stimulation with the PKC activator phorbol 12-myristate 13-acetate and increased by its inhibition with staurosporine or prolonged phorbol 12-myristate 13-acetate exposure. Surprisingly, epidermal growth factor (EGF) caused a strong dose-dependent augmentation of radioiodide transport, accompanied by extracellular signal-regulated kinase (ERK)-1/2 activation. Both effects were completely abrogated by specific MAP kinase kinase (MEK) inhibitors, which also reduced basal NIS function. Hence, radioiodide uptake levels could differ 24-fold, depending on ERK activity. Biotinylation-immunoblotting and confocal microscopy revealed that EGF increases plasma membrane–localized NIS without affecting total cellular levels. EGF stimulation was sufficient to enhance the killing effect of 131I on the cancer cells. Conclusion: Thus, PKC and ERK signaling play important roles in the regulation of NIS function, and control of these signaling pathways may help enhance the efficacy of radioiodide cancer therapy.Keywords
This publication has 20 references indexed in Scilit:
- α-Fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinomaGene Therapy, 2007
- Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivoEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- A perspective view of sodium iodide symporter research and its clinical implicationsActa Endocrinologica, 2006
- Phosphorylation of the Norepinephrine Transporter at Threonine 258 and Serine 259 Is Linked to Protein Kinase C-mediated Transporter InternalizationJournal of Biological Chemistry, 2006
- In vivo Radioiodide Imaging and Treatment of Breast Cancer Xenografts after MUC1-Driven Expression of the Sodium Iodide SymporterClinical Cancer Research, 2005
- Long-Term Radioiodine Retention and Regression of Liver Cancer after Sodium Iodide Symporter Gene Transfer in Wistar RatsCancer Research, 2004
- Neurotransmitter transporter trafficking: endocytosis, recycling, and regulationPharmacology & Therapeutics, 2004
- Post-transcriptional Regulation of the Sodium/Iodide Symporter by ThyrotropinJournal of Biological Chemistry, 2001
- Phosphorylation and Sequestration of Serotonin Transporters Differentially Modulated by PsychostimulantsScience, 1999
- Protein Kinase C-mediated Phosphorylation and Functional Regulation of Dopamine Transporters in Striatal SynaptosomesJournal of Biological Chemistry, 1997